Flibanserin is an agonist at 5-HT1A receptors and an antagonist at 5-HT2A receptors. Flibanserin is clinically used to treat hypoactive sexual disorder in females. Flibanserin also decreases dystonia induced by L-DOPA and quinelorane in animal models of Parkinson’s disease.
| Cas No. | 167933-07-5 |
|---|---|
| Purity | ≥98% |
| Formula | C20H21F3N4O |
| Formula Wt. | 390.40 |
| IUPAC Name | 3-[2-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one |
| Solubility | 15 mg/ml in ethanol, and 30 mg/ml in DMSO and DMF |
| Appearance | White Powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Gelez H, Clement P, Compagnie S, et al. Brain neuronal activation induced by flibanserin treatment in female rats. Psychopharmacology (Berl). 2013 Dec;230(4):639-52. PMID: 23857113.
Strecker K, Adamaszek M, Ohm S, et al. The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice. J Neural Transm. 2012 Nov;119(11):1351-9. PMID: 22569849.
Stahl SM, Sommer B, Allers KA. Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. J Sex Med. 2011 Jan;8(1):15-27. PMID: 20840530.
